Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

rilotumumab (AMG 102)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Amgen

Drug class:

c-MET inhibitor

Related drugs:

‹

›

MET expression	Gastroesophageal Junction Adenocarcinoma	MET expression	Gastroesophageal Junction Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET amplification	Gastroesophageal Junction Adenocarcinoma	MET amplification	Gastroesophageal Junction Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET expression	Gastric Adenocarcinoma	MET expression	Gastric Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET amplification	Gastric Adenocarcinoma	MET amplification	Gastric Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B